CN1879841A - A Chinese medicine for treating leukemia - Google Patents

A Chinese medicine for treating leukemia Download PDF

Info

Publication number
CN1879841A
CN1879841A CNA2006100127351A CN200610012735A CN1879841A CN 1879841 A CN1879841 A CN 1879841A CN A2006100127351 A CNA2006100127351 A CN A2006100127351A CN 200610012735 A CN200610012735 A CN 200610012735A CN 1879841 A CN1879841 A CN 1879841A
Authority
CN
China
Prior art keywords
radix
parts
root
fructus
chinese medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2006100127351A
Other languages
Chinese (zh)
Other versions
CN100421717C (en
Inventor
郭富红
郭志军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2006100127351A priority Critical patent/CN100421717C/en
Publication of CN1879841A publication Critical patent/CN1879841A/en
Application granted granted Critical
Publication of CN100421717C publication Critical patent/CN100421717C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

Disclosed is a Chinese medicament for treating leukemia, wherein the raw materials include antelope's bone, buffalo horn, earthworm, natural indigo, isatic root, zedoary, arctium fruit, subprostrate sophora root, bulb of edible tulip, oldenlandia, ganoderma lucidum, radix rubiae, fleece-flower root, ligustrum japonicum, matrimony vine, prepared rhizome of rehmannia, kudzu vine root, notoginseng, field thistle, asparagus root, lilyturf root, Chinese angelica root, gen-seng, astragalus root, donkey-hide gelatin, coix seed, licorice root, white atractylodes rhizome, poria cocos wolf, amomum fruit, dried rehmannia root, bark of peony root.

Description

The leukemic Chinese medicine of a kind of treatment
Technical field
The invention belongs to the leukemic medicine of a kind of treatment, specifically is the Chinese drugs agentia of feedstock production with the Chinese herbal medicine.
Background technology
Leukemia is called leukemia by modern medicine, it is a kind of disease that seriously jeopardizes human health, acute myeloblastic leukemia is arranged, chronic myelocytic leukemia, Lymphocytic leukemia thrombocytopenia, many types such as aplastic anemia, its cause is many by viral factor, due to the radiation factor, inherited genetic factors etc., also there is not effective Therapeutic Method at present.Present Therapeutic Method mainly is operation, radiotherapy, chemotherapy, though radiotherapy or chemotherapy can be killed the part cancerous cell, patient symptom is temporarily taken a turn for the better or alleviate, but when it kills and wounds cancerous cell, injured the normal immunocyte leukocyte, damaged the human righteousness, side effect is big, bring insufferable misery to patient, some critical patient is forced to therapy discontinued.Numerous medical personnels are at the effective ways of studying intensively, seek treatment, but also effectively do not cure leukemic medicament at present.
Summary of the invention
The purpose of this invention is to provide the leukemic Chinese medicine of a kind of treatment, screening has heat-clearing and toxic substances removing from Chinese herbal medicine, sets upright and gets rid of evils, the kidney tonifying spleen reinforcing, the natural plant of benefiting qi and nourishing blood, the effectively growth of anticancer, make patient's cancerous cell approaching, reach the purpose of healing to normal cell.
Medicine of the present invention is formed (consumption is a weight portion) by following component:
Os Caprae Saigae Tataricae 6-15 part, Cornu Bubali 5-10 part, Lumbricus 6-10 part, Indigo Naturalis 3-9 part, Radix Isatidis 10-20 part, Rhizoma Curcumae 6-10 part, the other sub-5-15 part of cattle, Radix Sophorae Tonkinensis 6-15 part, Pseudobulbus Cremastrae Seu Pleiones 3-6 part, Herba Hedyotidis Diffusae 10-30 part, Ganoderma 5-10 part, Radix Rubiae 6-10 part, Radix Polygoni Multiflori 9-15 part, Fructus Ligustri Lucidi 10-15 part, Fructus Lycii 6-15 part, Radix Rehmanniae Preparata 6-10 part, Radix Puerariae 5-10 part, Radix Notoginseng 5-10 part, Herba Cirsii 6-10 part, Radix Asparagi 10-15 part, Radix Ophiopogonis 10-15 part, Radix Angelicae Sinensis 6-15 part, Radix Ginseng 3-9 part, Radix Astragali 10-30 part, Colla Corii Asini 6-10 part, Semen Coicis 10-20 part, Radix Glycyrrhizae 3-6 part, Rhizoma Atractylodis Macrocephalae 10-15 part, Poria 6-10 part, Fructus Amomi 3-6 part, Radix Rehmanniae 10-15 part, Cortex Moutan 3-6 part.
The formula optimization weight proportion scope of preparation medicine of the present invention is:
Os Caprae Saigae Tataricae 8-12 part, Cornu Bubali 7-9 part, Lumbricus 7-8 part, Indigo Naturalis 5-7 part, Radix Isatidis 14-18 part, Rhizoma Curcumae 7-9 part, the other sub-8-12 part of cattle, Radix Sophorae Tonkinensis 8-12 part, Pseudobulbus Cremastrae Seu Pleiones 3-6 part, Herba Hedyotidis Diffusae 10-30 part, Ganoderma 5-10 part, Radix Rubiae 8-9 part, Radix Polygoni Multiflori 11-12 part, Fructus Ligustri Lucidi 13-14 part, Fructus Lycii 9-11 part, Radix Rehmanniae Preparata 7-9 part, Radix Puerariae 7-9 part, Radix Notoginseng 7-9 part, Herba Cirsii 7-9 part, Radix Asparagi 11-14 part, Radix Ophiopogonis 12-14 part, Radix Angelicae Sinensis 8-12 part, Radix Ginseng 5-7 part, Radix Astragali 15-25 part, Colla Corii Asini 7-9 part, Semen Coicis 13-17 part, Radix Glycyrrhizae 4-5 part, Rhizoma Atractylodis Macrocephalae 12-14 part, Poria 7-9 part, Fructus Amomi 4-5 part, Radix Rehmanniae 12-14 part, Cortex Moutan 4-5 part.
The optimum weight proportioning of medicine of the present invention is:
10 parts of Os Caprae Saigae Tataricaes, 8 parts of Cornu Bubalis, 9 parts of Lumbricuss, 6 parts of Indigo Naturaliss, 15 parts of Radix Isatidis, 8 parts of Rhizoma Curcumae, 10 parts of the other sons of cattle, 10 parts of Radix Sophorae Tonkinensiss, 5 parts of Pseudobulbus Cremastrae Seu Pleioness, 20 parts of Herba Hedyotidis Diffusaes, 7 parts of Ganodermas, 8 parts in Radix Rubiae, 12 parts of Radix Polygoni Multiflori, 13 parts of Fructus Ligustri Lucidi, 10 parts of Fructus Lyciis, 8 parts in Radix Rehmanniae Preparata, 8 parts of Radix Puerariaes, 7 parts of Radix Notoginseng, 8 parts of Herba Cirsiis, 12 parts of Radix Asparagis, 12 parts of Radix Ophiopogonis, 11 parts of Radix Angelicae Sinensis, 6 parts of Radix Ginsengs, 20 parts of the Radixs Astragali, 8 parts in Colla Corii Asini, 15 parts of Semen Coiciss, 5 parts in Radix Glycyrrhizae, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts in Poria, 5 parts of Fructus Amomis, 13 parts in the Radix Rehmanniae, 5 parts of Cortex Moutans.
Pharmacology analysis: the present invention is at first with Cornu Bubali, Cornu Saigae Tataricae salty-cold, closing Pheretima clearly thoroughly is good at network and walks marrow, the oblique heat effect of the bright marrow of straight folding is a priming, and draw flavors such as Indigo Naturalis, Radix Isatidis, Folium Isatidis, the other son of cattle, Herba Hedyotidis Diffusae, Rhizoma Curcumae, Ganoderma, nature and flavor bitter cold, heat-clearing and toxic substances removing wherein contain indirubin, cancerous cell there is direct killing effect, simultaneously cancerous cell is transformed to normal cell.Radix Polygoni Multiflori, Fructus Lycii, Radix Asparagi, Radix Ophiopogonis can strengthen the phagocytic activity that gulps down of reticuloendothelial system cell, and the rising peripheral leukocytes improves immunity, strengthen cardiorenal function and recover.Radix Notoginseng, Radix Rubiae, Herba Cirsii, Radix Astragali clearing away heat and cooling blood, blood circulation promoting and blood stasis dispelling, hemostasis.Radix Rehmanniae Preparata, Radix Ginseng, Colla Corii Asini, Radix Angelicae Sinensis, the Radix Rehmanniae, Semen Coicis benefiting qi and nourishing blood, harmonizing the liver and spleen makes QI and blood, and lymphocyte normally moves.The Radix Puerariae expelling pathogenic factors from muscles for reducing heat is dispersed virus, and heresy goes just to deposit, and human body is normally moved.Prescription integral body has heat-clearing and toxic substances removing, direct killing cancer cell, sets upright and gets rid of evils, and recovers the effect of human body.
From the principle of pestilence theory treatment, in conjunction with pestilence defensive-qi-nutrient-blood change of disease rule, leukemia is in marrow blood battalion headquarter position, due to warm viral cancerous cell corrodes.Employing is got rid of evils and is gone out, and allows fall back on blood system by the oblique fever virus of bone marrow, and blood system moves back battalion again and divides, and is divided by battalion and moves back edema caused by disorder of QI, is moved back by edema caused by disorder of QI and defends branch, evilly disperses by going from defending branchs, and heresy is moved back body and pacified.
The specific embodiment
After medicine of the present invention makes according to set of dispense, can take by fried according to a conventional method one-tenth decoction, also can manufacture the Chinese medicine pill according to a conventional method, the Chinese medicine electuary is taken, can also daily dosage effective component extracting according to Chinese herbal medicine after, make capsule and quantitatively take on time.
Use prescription treatment leukemia 20 examples of the present invention, cure rate reaches 66%, and effective percentage reaches 90%, has 2 routine patients not good through therapeutic effect, the treatment of transferring from one hospital to another.
Model case: thank * *, the man, 27 years old, went to a doctor in November, 2004
Aplastic anemia during prescription on individual diagnosis, the face pale asphyxia, not seeing has bleeding, the systemic sustained heating.Use the fried medicament of Chinese medicine of the present invention, method according to routine is fried, and one day twice, each potion of morning and evening, further consultation after taking medicine continuously 7, sb.'s illness took a favorable turn after conscious the taking medicine, and after taking medicine again 7, resembles disappearance to the positive disease of examination in hospital, recover certain work capacity after half a year, physical recovery is normal after 1 year, does not have recurrence so far, can operate as normal.

Claims (3)

1, the leukemic Chinese medicine of a kind of treatment is characterized in that it is the medicament of being made by the following weight proportion raw material:
Os Caprae Saigae Tataricae 6-15 part, Cornu Bubali 5-10 part, Lumbricus 6-10 part, Indigo Naturalis 3-9 part, Radix Isatidis 10-20 part, Rhizoma Curcumae 6-10 part, the other sub-5-15 part of cattle, Radix Sophorae Tonkinensis 6-15 part, Pseudobulbus Cremastrae Seu Pleiones 3-6 part, Herba Hedyotidis Diffusae 10-30 part, Ganoderma 5-10 part, Radix Rubiae 6-10 part, Radix Polygoni Multiflori 9-15 part, Fructus Ligustri Lucidi 10-15 part, Fructus Lycii 6-15 part, Radix Rehmanniae Preparata 6-10 part, Radix Puerariae 5-10 part, Radix Notoginseng 5-10 part, Herba Cirsii 6-10 part, Radix Asparagi 10-15 part, Radix Ophiopogonis 10-15 part, Radix Angelicae Sinensis 6-15 part, Radix Ginseng 3-9 part, Radix Astragali 10-30 part, Colla Corii Asini 6-10 part, Semen Coicis 10-20 part, Radix Glycyrrhizae 3-6 part, Rhizoma Atractylodis Macrocephalae 10-15 part, Poria 6-10 part, Fructus Amomi 3-6 part, Radix Rehmanniae 10-15 part, Cortex Moutan 3-6 part.
2, the leukemic Chinese medicine of a kind of treatment is characterized in that wherein the weight proportion of each raw material is:
Os Caprae Saigae Tataricae 8-12 part, Cornu Bubali 7-9 part, Lumbricus 7-8 part, Indigo Naturalis 5-7 part, Radix Isatidis 14-18 part, Rhizoma Curcumae 7-9 part, the other sub-8-12 part of cattle, Radix Sophorae Tonkinensis 8-12 part, Pseudobulbus Cremastrae Seu Pleiones 3-6 part, Herba Hedyotidis Diffusae 10-30 part, Ganoderma 5-10 part, Radix Rubiae 8-9 part, Radix Polygoni Multiflori 11-12 part, Fructus Ligustri Lucidi 13-14 part, Fructus Lycii 9-1 part, Radix Rehmanniae Preparata 7-9 part, Radix Puerariae 7-9 part, Radix Notoginseng 7-9 part, Herba Cirsii 7-9 part, Radix Asparagi 11-14 part, Radix Ophiopogonis 12-14 part, Radix Angelicae Sinensis 8-12 part, Radix Ginseng 5-7 part, Radix Astragali 15-25 part, Colla Corii Asini 7-9 part, Semen Coicis 13-17 part, Radix Glycyrrhizae 4-5 part, Rhizoma Atractylodis Macrocephalae 12-14 part, Poria 7-9 part, Fructus Amomi 4-5 part, Radix Rehmanniae 12-14 part, Cortex Moutan 4-5 part.
3, the leukemic Chinese medicine of a kind of treatment is characterized in that wherein the weight proportion of each raw material is:
10 parts of Os Caprae Saigae Tataricaes, 8 parts of Cornu Bubalis, 9 parts of Lumbricuss, 6 parts of Indigo Naturaliss, 15 parts of Radix Isatidis, 8 parts of Rhizoma Curcumae, 10 parts of the other sons of cattle, 10 parts of Radix Sophorae Tonkinensiss, 5 parts of Pseudobulbus Cremastrae Seu Pleioness, 20 parts of Herba Hedyotidis Diffusaes, 7 parts of Ganodermas, 8 parts in Radix Rubiae, 12 parts of Radix Polygoni Multiflori, 13 parts of Fructus Ligustri Lucidi, 10 parts of Fructus Lyciis, 8 parts in Radix Rehmanniae Preparata, 8 parts of Radix Puerariaes, 7 parts of Radix Notoginseng, 8 parts of Herba Cirsiis, 12 parts of Radix Asparagis, 12 parts of Radix Ophiopogonis, 11 parts of Radix Angelicae Sinensis, 6 parts of Radix Ginsengs, 20 parts of the Radixs Astragali, 8 parts in Colla Corii Asini, 15 parts of Semen Coiciss, 5 parts in Radix Glycyrrhizae, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts in Poria, 5 parts of Fructus Amomis, 13 parts in the Radix Rehmanniae, 5 parts of Cortex Moutans.
CNB2006100127351A 2006-05-17 2006-05-17 A Chinese medicine for treating leukemia Expired - Fee Related CN100421717C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006100127351A CN100421717C (en) 2006-05-17 2006-05-17 A Chinese medicine for treating leukemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100127351A CN100421717C (en) 2006-05-17 2006-05-17 A Chinese medicine for treating leukemia

Publications (2)

Publication Number Publication Date
CN1879841A true CN1879841A (en) 2006-12-20
CN100421717C CN100421717C (en) 2008-10-01

Family

ID=37518342

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100127351A Expired - Fee Related CN100421717C (en) 2006-05-17 2006-05-17 A Chinese medicine for treating leukemia

Country Status (1)

Country Link
CN (1) CN100421717C (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101181516B (en) * 2007-11-15 2011-03-16 张春秀 Chinese medicine prescription orally taken for curing leukaemia
CN102048977A (en) * 2011-01-12 2011-05-11 徐祖书 Chinese medicinal composition for treating chronic myeloid leukemia
CN102078542A (en) * 2011-01-12 2011-06-01 徐祖书 Traditional Chinese medicine combination for treating acute granulocyte AML-M4 leukemia
CN102600362A (en) * 2012-02-02 2012-07-25 焦成玉 Traditional Chinese medicine oral liquid for treating leukemia and preparation method thereof
CN102772685A (en) * 2012-07-16 2012-11-14 梁艳龙 Traditional Chinese medicinal preparation for treating aplastic anemia
CN103736038A (en) * 2014-02-19 2014-04-23 段寒 Chinese medicine combination for curing leukemia, preparation and application thereof
CN105663419A (en) * 2016-03-25 2016-06-15 杨忠雅 Formula for pure traditional Chinese medicines capable of generating new blood, dispelling extravasated blood and treating leukemia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1216620C (en) * 2002-08-06 2005-08-31 王凯 Composite medicine for treating leukemia

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101181516B (en) * 2007-11-15 2011-03-16 张春秀 Chinese medicine prescription orally taken for curing leukaemia
CN102048977A (en) * 2011-01-12 2011-05-11 徐祖书 Chinese medicinal composition for treating chronic myeloid leukemia
CN102078542A (en) * 2011-01-12 2011-06-01 徐祖书 Traditional Chinese medicine combination for treating acute granulocyte AML-M4 leukemia
CN102078542B (en) * 2011-01-12 2012-05-30 徐祖书 Traditional Chinese medicine combination for treating acute granulocyte AML-M4 leukemia
CN102600362A (en) * 2012-02-02 2012-07-25 焦成玉 Traditional Chinese medicine oral liquid for treating leukemia and preparation method thereof
CN102600362B (en) * 2012-02-02 2014-01-08 焦成玉 Traditional Chinese medicine oral liquid for treating leukemia and preparation method thereof
CN102772685A (en) * 2012-07-16 2012-11-14 梁艳龙 Traditional Chinese medicinal preparation for treating aplastic anemia
CN102772685B (en) * 2012-07-16 2014-07-02 梁艳龙 Traditional Chinese medicinal preparation for treating aplastic anemia
CN103736038A (en) * 2014-02-19 2014-04-23 段寒 Chinese medicine combination for curing leukemia, preparation and application thereof
CN103736038B (en) * 2014-02-19 2016-01-20 段寒 Treat leukemic Chinese medicine composition, its preparation and application
CN105663419A (en) * 2016-03-25 2016-06-15 杨忠雅 Formula for pure traditional Chinese medicines capable of generating new blood, dispelling extravasated blood and treating leukemia

Also Published As

Publication number Publication date
CN100421717C (en) 2008-10-01

Similar Documents

Publication Publication Date Title
CN1124153C (en) Medicinal composition for restoring cardiac collaterals and its application
CN1330347C (en) Gongbu ointment
CN100421717C (en) A Chinese medicine for treating leukemia
CN1651064A (en) Medicinal composition for treating tumour and its preparation method
CN1840126A (en) Chinese medicine for treating amblyopia and myopia
CN102614442B (en) Traditional Chinese drug capsules with effects of immunity enhancing, blood reinforcing and antiemesis
CN1150018C (en) Medicine for treating tachy-arrhythmia
CN104225166A (en) Chinese medicine composition for treating amenorrhea and preparation method thereof
CN1049827C (en) Anti-cancer powder
CN1134824A (en) Oral liquid for regulating women's sexual function
CN101623352A (en) Medicine for treating acne and preparation method thereof
CN1082376C (en) Pathogenic factor eliminating and healthy energy supporting anticancer medicine
CN1260983A (en) Process for preparing leukemia medicines
CN1077896A (en) Medicine for psoriasis and manufacture method
CN1127344C (en) Oral pill for curing diabetes and its complication
CN101745080A (en) Chinese patent medicine for treating leukemia
CN101199761B (en) Drug for treating arteriosclerosis
CN1052914C (en) Suyuwan pill for curing leucoderma
CN101314010A (en) Liquefied clearing pill
CN1293908C (en) Cancer preventing and curing Chinese medicine of two snakes and Ganoderma Lucidum seu Japonicum
CN1219540C (en) Chinese medicine for treating leukoderma and the prepn process of the tablets
CN1151813C (en) Traditional Chinese medicine composition for curing insomnia
CN1062172C (en) Medicine for treating cervical spondylopathy
CN1113804A (en) Antianemic powder and its preparing method
CN1124155C (en) Medicine for treating leukoderma and preparing process

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081001

Termination date: 20140517